I think the information on the company I posted in the thread moved the market, not your comments Pete, but you are joking of course.....
Perhaps this share price does not move permanently higher until investors literally see qtr after qtr of Bio Horizons revenues piling in. Whatever. I have the patience of an Ox and have slowly bought more small clips of OCC myself below 40's since this deal - and of course bought a bit more before posting this information, that frankly I should not be first to find. Once again this utterly beats my expectations. Never did I expect a top 5 dental pharma deal on Striate. Never did I expect Sriate to be front and centre of Bio Horizon's website, but rather buried in the back of their catalogues, with OCC pushing hard to get exposure.
This is a massive beat on marketing expectations for Striate and should raise anyone's prior modelling/expectations of revenues therein. If this drifts back to $0.40 then the markets are a joke (ergo some investors quite stupid). When investors are selling because they are being a bit short-sighted, selling on margin calls, or structural reasons (index rebalances), these are the times to buy and make money longer-term. Sorry to be rude, but investors selling OCC at $0.40 really are being a bit stupid given the information at hand on future likely earnings.
(Dear OCC investors suggesting a buyback. Please, for your own sakes, read a decent finance book to understand the typical evolutionary lifespan of a company within the global finance system we call capitalism and where this company is in that)
OCC Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
(20min delay)